Preclinical In-vivo Imaging Market Report

Global Preclinical In-vivo Imaging Market Size

The size of the global preclinical in-vivo imaging market was valued at USD 944.86 million in 2025. The global market size is further forecasted to grow at a CAGR of 5.76% from 2025 to 2034 and be worth 1564.08 million by 2034 from USD 999.28 million in 2026.

MARKET DRIVERS

The importance of the development of molecular imaging in small animals with basic strategies of non-invasive in vivo imaging methods is a primary factor for the preclinical in-vivo imaging market. In recent years, imaging techniques have been prominent in studying and launching potential treatment procedures using small animal models like mice and rats. The non-invasive imaging techniques are highly impactful in learning the treatment effects that reduce the harm to the animals during the research. Researchers can gain huge knowledge through the continuous monitoring of the disease progression and help to develop an innovative treatment procedure in a relatively short time. Preclinical in vivo imaging market share is also propelled by the increasing support from the government authorities as it reduces the use of a varied number of animals for specific analysis in research studies. The emergence of the most advanced technologies is ascribed to bolstering the growth rate of the preclinical in-vivo imaging market.

Artificial intelligence, which was integrated into the pharmaceutical and healthcare systems, is ensuring the transformation of the structure of the preclinical in-vivo imaging techniques to another level. AI can provide huge amounts of data required for researchers in very little time. They can perform the work more quickly than usual with the accurate data given by the AI. In addition, high investments from both private and public organizations in the development of new drugs or treatment procedures enhance the growth rate of the preclinical in-vivo imaging market. The growing prevalence of various chronic diseases and the need to launch innovative treatment procedures to combat or reduce the risk of increasingly rising diseases are contributing to boosting the size of the market.

MARKET RESTRAINTS

Supply chain disruptions and difficulty in the availability of raw materials are hindering the growth rate of the preclinical in-vivo imaging market. Also, the cost of research activities is incredibly high, and the lack of support from the government in some countries may hamper the market size. Government authorities are taking too long to approve a new drug or any treatment procedures. Authorities are taking stringent actions to promote better and more effective healthcare solutions that are likely to slow down the growth rate of the market. Also, reluctance to adopt new changes and lack of proper knowledge over the collection of data through advanced technology may likely decline the share of the preclinical in-vivo imaging market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Modality Insights

The micro-ultrasound segment is anticipated to grow with the fastest CAGR over the forecast period. It would be a significant contributor to the global market for preclinical In-vivo imaging. Micro-ultrasound is a smaller ultrasound version with a wider variety of applications, particularly in small animal model research. Some smaller versions of imaging methods improve the techniques ' efficacy. These often decrease the number of animals required for a specific study.

By Reagent Insights

Based on the reagent, the Ultrasound Contrast Agents segment is anticipated to dominate the global market owing to their increased application in multiple imaging methods.

REGIONAL ANALYSIS

Regionally, North America holds the largest share of the global preclinical imaging market, followed by Europe. North America dominates the global market given the rapid adoption by end-users of several types of modalities, technological advancement, and increased prevalence of chronic diseases like cancer, cardiovascular disease, and many others.

Factors including rising R&D activities by big pharma and biotech companies in developing nations and increased government funding for the pharmaceutical industry's development are stimulating the growth of the preclinical imaging market in the Asia-Pacific region.

KEY MARKET PLAYERS

Companies are currently playing a leading role in the global preclinical in-vivo imaging market include

• Aspect Imaging
• Biospace Lab S.A.
• Bruker Corporation
• LI-COR Biosciences
• Mediso Ltd.
• MILabs B.V.
• MR Solutions Ltd.
• PerkinElmer, Inc.
• TriFoil Imaging
• FUJIFILM VisualSonics, Inc.

RECENT HAPPENINGS IN THIS MARKET

• Aspect Imaging, one of the market players in designing and developing compact magnetic resonance systems for preclinical, medical, and industrial applications, announced in September 2017 that Quantum Analytics will be its exclusive U.S. distributor for the Industrial product portfolio of Aspect Imaging.
• In mid-2019, Kawasaki Medical University, the research center for state-of-the-art medical science and services in Yokohama, acquired an ultra-high-resolution E-Class U-SPECT6/CT system for preclinical imaging and installed the first MILabs E-Class U-SPECT6/CT system in Japan.

MARKET SEGMENTATION

This research report on the global preclinical in-vivo imaging market has been segmented and sub-segmented based on the modality, reagent, and region.

By Modality

• Optical imaging
  • Bioluminescence/fluorescence imaging systems
  • Standalone fluorescence imaging systems
  • Optical + X-ray/optical + CT imaging systems
• Nuclear imaging
  • Micro-PET systems (standalone PET, PET/CT, and PET/MRI)
  • Micro-SPECT systems (standalone SPECT, SPECT/CT, and SPECT/MRI)
  • Tri-modality (PET/SPECT/CT) imaging systems
• Micro-MRI
• Micro-CT
• Micro-ultrasound
• Photoacoustic
• Magnetic particle imaging systems

By Reagent

• Optical imaging reagents
  • Bioluminescent reagents
  • Fluorescent imaging reagents
• Nuclear imaging reagents
  • Preclinical PET tracers
  • Preclinical SPECT probes
• MRI contrast agents
• Ultrasound contrast agents
• CT contrast agents

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa